TriangleNCT03552393 · CITED IN SOURCE DOCUMENTS
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2022-03-07
Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient
Number of Participants With an Average Hb Concentration During the Evaluation Period Within ± 1 g/dL of Their Baseline Hb and Above, Within or Below the Range of 10-12 g/dL
Mean Hb Values and Change From Baseline
Change in Mircera Dose Over Time
Ratio of Mircera Starting Dose (Week 1) to the Dose at Week 17
Number of Participants With Adverse Events by Severity as Assessed by Highest World Health Organization (WHO) Toxicity Grade
Bioavailability (F) of Mircera in Pediatric Participants Based on Population PK Model
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Pediatric participants 3 months to 17 years of age with clinically stable chronic renal anemia * CKD with estimated glomerular filtration rate (eGFR) of \< 45 mL/min/1.73 m2 (determined by the Bedside Schwartz formula) or dialysis treatment for at least 8 weeks before the first dose of Mircera * For participants on peritoneal dialysis (PD): a weekly Kt/V≥ 1.8 * For participants on hemodialysis (HD): adequate HD, urea reduction ratio (URR) \> 65% or Kt/V \> 1.2 for participants on HD three times per week. Participants with fewer than or more than three HD sessions per week should have a weekly Kt/V≥ 3.6. * Baseline Hb concentration 10.0-12.0 g/dL determined from the mean of two Hb values measured at Visit 1 (Week -3) and Visit 2 (Week -1) * Stable SC maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa with the same dosing interval for at least 6 weeks before the first dose of Mircera * Stable dose of epoetin alfa, epoetin beta, or darbepoetin alfa treatment with no weekly dose change \> 25% (increase or decrease) for at least 4 weeks before the first dose of Mircera * Adequate iron status defined as ferritin≥100 ng/mL or transferrin saturation (TSAT)≥ 20% (or percentage of hypochromic red cells \< 10%); mean of two values measured during screening. Exclusion Criteria: * Overt gastrointestinal bleeding within 8 weeks before screening or during the screening period * RBC transfusions within 8 weeks before screening or during the screening period * Hemoglobinopathies (e.g., homozygous sickle-cell disease, thalassemia of all types) Hemolytic anemia, Active malignant disease * PD subjects with an episode of peritonitis within the past 30 days prior to screening and/or during the screening period * Uncontrolled or symptomatic inflammatory disease (e.g., systemic lupus erythematosus) * Uncontrolled hypertension as assessed by the investigator * Epileptic seizures within 3 months prior to screening and during the screening period * Administration of any investigational drug within 4 weeks prior to screening or planned during the study * Severe hyperparathyroidism (intact parathyroid hormone \[PTH\]≥ 1000 pg/mL or whole PTH≥ 500 pg/mL) or biopsy-proven bone marrow fibrosis * Kidney transplant with use of immunosuppressive therapies known to exacerbate anemia * Known hypersensitivity to recombinant human erythropoietin (EPO), polyethylene glycol, or any constituent of the study drug formulation * Anti-EPO antibody (AEAB)-mediated pure red cell aplasia (PRCA) or history of AEAB mediated PRCA or positive AEAB test result in the absence of PRCA * High likelihood of early withdrawal or interruption of the study (e.g., planned living donor kidney transplant within 5 months of study start) * Planned elective surgery during the entire study period
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 3 Months
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- Mircera will be administered subcutaneously once every 4 weeks
- intervention Names
- Drug: Mircera
- label
- Mircera
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Mircera
- description
- The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
- name
- Mircera
- other Names
- Methoxy polyethylene glycol-epoetin beta
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 40
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The Hb change from baseline was calculated on a per-participant basis using an individual's average for both the baseline and evaluation periods and taking the difference. The baseline period was defined as the time between the day of first study dose and the previous 35 days. The evaluation period was defined as the period between Week 17 and Week 21, inclusive.
- measure
- Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient
- time Frame
- Baseline up to Week 21
- secondary Outcomes
- description
- Number of participants with an average Hb concentration during the evaluation period within ± 1 g/dL of their baseline Hb is reported as well as the number of participants with an average Hb concentration above, within or below the range of 10-12 g/dL. The evaluation period was defined as the period between Week 17 and Week 21 inclusive.
- measure
- Number of Participants With an Average Hb Concentration During the Evaluation Period Within ± 1 g/dL of Their Baseline Hb and Above, Within or Below the Range of 10-12 g/dL
- time Frame
- Week 17 up to Week 21
- description
- The mean Hb concentration over time and the mean change in Hb from baseline over time are presented.
- measure
- Mean Hb Values and Change From Baseline
- time Frame
- Baseline, Weeks 3, 5, 9, 13, 17, 19, 21, 25, 29, 33, 37, 41, 45
- description
- A dose change was defined as a change in the administered dose strength compared to the preceding dose.
- measure
- Change in Mircera Dose Over Time
- time Frame
- Week 1 to Week 17
- description
- The ratio of Mircera dose was calculated as the median (min-max) ratio of starting dose (Week 1) to the dose at Week 17. Participants who withdrew before Week 17 or who were not administered a Mircera dose at Week 17 visit due to the applicable dose adjustment rules were excluded from the ratio computation.
- measure
- Ratio of Mircera Starting Dose (Week 1) to the Dose at Week 17
- time Frame
- Week 1, Week 17
- description
- An adverse event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, any new disease, or exacerbation of existing disease (a worsening in the character, frequency, or severity of a known condition), recurrence of an intermittent medical condition or any deterioration in a laboratory value or other clinical test.
- measure
- Number of Participants With Adverse Events by Severity as Assessed by Highest World Health Organization (WHO) Toxicity Grade
- time Frame
- Baseline up to Week 45
- description
- Bioavailability (F) is defined as the percentage of the administered drug, that reaches the systemic circulation. A population PK model was developed for Mircera that adequately describes pediatric data: a 1-compartment model with first order absorption and elimination processes. The bioavailability (F) was estimated using all the data points listed under time frame using the population PK model.
- measure
- Bioavailability (F) of Mircera in Pediatric Participants Based on Population PK Model
- time Frame
- Pre-dose at Week 1, 9, 17; Post-dose at Week 3, Week 19 and additional sample taken between 24 hours and 5 days at participant's convenience
Full study description
- brief Summary
- Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.
Source references
- references
- citation
- Warady BA, Meyer Reigner S, Tirodkar C, Drozdz D. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Am J Kidney Dis. 2023 Jun;81(6):684-694.e1. doi: 10.1053/j.ajkd.2022.11.006. Epub 2022 Dec 29.
- pmid
- 36587890
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-4baf95812dbd8edb522e
- requested nct id
- NCT03552393
- primary nct id
- NCT03552393
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 84da1bf3a270326c8732adb5bc58bc29d8e134c6e5873e36f9c1337cf8e4add5
- payload
- application numbers
- BLA125164
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-4baf95812dbd8edb522e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03552393
- occurrences
- context exact
- . Seventy-seven percent (77%) of patients had a dose adjustment (either a dose decrease, increase or both). A second open-label, single-arm, multicenter study (NCT03552393) was performed to ascertain the optimal starting dose of Mircera administered subcutaneously for the maintenance treatment of anemia in 40 pediatric patients w
- end
- 9818
- exact text
- NCT03552393
- start
- 9807
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/28/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e4718f278666e7868a115a8a0f136678de33f62f724c24f18a669c8edfd02a7c
- spl effective time
- 20260814
- spl set id
- 22c56f2a-f73c-60e7-e054-00144ff88e88
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-865d9af41aa2c5e5c3ac
- requested nct id
- NCT03552393
- primary nct id
- NCT03552393
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 86ecdb0032c50fd61901cec89b6e7b7cf0a951c05b50253b9a12d188bc044d25
- payload
- application numbers
- BLA125164
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-865d9af41aa2c5e5c3ac
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03552393
- occurrences
- context exact
- study (NCT00717366), blood samples to measure anti-Mircera and anti-EPO antibodies were collected on Week 1, Week 13, Week 21 and Week 73. In the second study (NCT03552393), they were measured at Week 1, Week 9, Week 21, and Week 45. No patients tested positive at any time during the first study. In the second study, two patients
- end
- 4592
- exact text
- NCT03552393
- start
- 4581
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/28/clinical_pharmacology/0
- source kind
- fda_spl_label
- source record id
- 0a85c353-f0fe-4bdb-843e-47264785e209
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- d9d874bacce1c98549cacd3353194d995e96ecd8a0bb8e5a700318efbfd608f5
- spl effective time
- 20260814
- spl set id
- 22c56f2a-f73c-60e7-e054-00144ff88e88
Preserved source evidence · Not medical advice